Business Daily.
.
A+ R A-

Newron Receives Positive Opinion for Orphan Medicinal Product Designation for Sarizotan to Treat Patients with Rett Syndrome from the Committee for Orphan Medicinal Products from the European Medicines Agency

E-mail Print PDF
MILAN--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A., a research and development company focused on novel CNS and pain therapies, announces that it has received a positive opinion for its New Chemical Entity Sarizotan.

imageimage
Grow Your Business with Times Media
Business Daily Media